Reuters -- Bayer BAYG.DE and Johnson & Johnson have ruled out delivering data requested by U.S. regulators on their anti-blood-clotting pill Xarelto this year, playing it safe for the potential blockbuster’s largest market.
Reuters -- Bayer BAYG.DE and Johnson & Johnson have ruled out delivering data requested by U.S. regulators on their anti-blood-clotting pill Xarelto this year, playing it safe for the potential blockbuster’s largest market.
